Harmony Biosciences Q3 net revenue $186M (+16% YoY); reiterates FY2024 guidance $700-720M

Harmony Biosciences Holdings, Inc.

2024-Q3 EPS reported $1.66 revenue$513,467,000

GAAP net income $46.1M ($0.79 diluted EPS) vs $38.5M ($0.63) in Q3 2023; non-GAAP adjusted EPS $1.03.
Average WAKIX patients ~6,800 (+250 sequentially); cumulative net revenue surpasses $2B since 2019 launch.
On track to submit sNDA for pitolisant in idiopathic hypersomnia in Q4 2024; LTS data show sustained efficacy.
Pipeline: EPX-100 Phase 3 for Dravet syndrome (data 2026); Phase 3 for LGS to start by year-end; ZYN-002 topline mid-2025.
Reiterates FY2024 net product revenue guidance of $700-$720 million.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.